M. Kudo
Hepatology · 2003–2022
A researcher in the Science corpus: 26 papers; trusts 2 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Hepatology — 249 citations into it; #117 of 151 by trust here, #7 by citations
- Epidemiology — 196 citations into it
Whom M. Kudo trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts M. Kudo overall
Papers from M. Kudo's perspective
Ordered by how strongly the researchers M. Kudo trusts endorse each paper. Same corpus, a different order for every researcher.
- Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
- Novel advancements in the management of hepatocellular carcinoma in 2008. (Journal of Hepatology)
- Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. (American Journal of Epidemiology)
- Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. (Gastroenterology)
- Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage Transplantation (Annals of Surgery)
- The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients (Hepatology)
- Noninvasive assessment of liver fibrosis (Hepatology)
- Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. (Journal of Hepatology)
- Diagnosis and treatment of hepatocellular carcinoma. (Gastroenterology)
- Molecular Targeted Therapies in Hepatocellular Carcinoma (Hepatology)
Their papers
- Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. (2013) — 698 citations
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010) — 1,052 citations
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. (2022) — 1,114 citations
- Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. (2021) — 1,360 citations
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. (2021) — 898 citations
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC (2021) — 1,066 citations
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. (2020) — 5,608 citations
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (2020) — 898 citations
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020) — 879 citations
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. (2019) — 1,410 citations
- CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) (2019) — 616 citations
- Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial (2019) — 629 citations
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) — 1,383 citations
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. (2018) — 2,061 citations
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) — 3,215 citations
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (2017) — 3,695 citations
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017) — 2,032 citations
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. (2015) — 754 citations
- Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study (2015) — 1,194 citations
- WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. (2015) — 713 citations